Likelihood of Approval and Phase Transition Success Rate Model – Incobotulinumtoxin A in Unspecified Musculoskeletal Disorders
Powered by ![]()
Unlock hidden opportunities in the LoA industry
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Incobotulinumtoxin A in Unspecified Musculoskeletal Disorders report and make more profitable business decisions.
This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


Incobotulinumtoxin A in Unspecified Musculoskeletal Disorders Drug Details:
Incobotulinumtoxin A (Xeomin/Xeomeen/Bocouture) belongs to musculoskeletal system agent. Incobotulinumtoxin A the active ingredient in the formulation is botulinum toxin type A produced from fermentation of Hall strain. It is formulated as lyophilized powder for solution for intramuscular route of administration. Incobotulinumtoxin A is indicated for the treatment of adults with cervical dystonia to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naïve and previously treated patients and for the treatment of adults with blepharospasm who were previously treated with onabotulinumtoxinA (Botox). It is indicated for the treatment of upper limb spasticity and also indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy. It is indicated for the treatment of chronic sialorrhea in adults and children and pediatric spasticity of the upper and lower limb in children.It is under development for the treatment of prevention of cervical dystonia, hypersalivation, atrial fibrillation (AF) after cardiac surgery, improvement of calf muscle hypertrophy, essential tremor of the upper limb, upper limb spasticity, hemifacial spasm, migraine, blepharospasm and lower limb spasticity. The drug candidate is also under development for the treatment of degenerative rotator cuff disease and androgenic alopecia.The drug candidate was also under development for treatment of snoring, notalgia paresthetica, brachial plexus neuritis, lateral epicondylitis, rosacea, focal cancer pain, foot dystonia in parkinson disease, trigeminal neuralgia, restless leg syndrome and spastic equine and equinovarus foot deformation in pediatric cerebral palsy, enlarged pores and excessive sebum production in the face and paratonic rigidity in people with advanced cognitive impairment. It is administered through intramuscular, intradermal and subcutaneous routes.
Report Coverage
The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.
The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.
| Quick View – Incobotulinumtoxin A LOA Data | |||||
| Report Segments |
|
||||
| Drug Name |
|
||||
| Administration Pathway |
|
||||
| Therapeutic Areas |
|
||||
| Key Manufacturers |
|
||||
| Drug Development Status |
|
||||
Reasons to Buy
- Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
- Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
- Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
- Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.
Scope
- Drug Details: Drug name, Drug type, Intervention type
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports